Lv6
1620 积分 2024-03-19 加入
Machine learning models for predicting chemotherapy-induced adverse drug reactions in colorectal cancer patients
29天前
已完结
Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer
3个月前
已完结
Health-Related Quality of Life in Chronic Urticaria: A Systematic Review and Meta-Analysis
5个月前
已完结
Abstract P6-18-11: Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+ breast cancer patients with prior anti-HER2 therapy
6个月前
已完结
DESTINY-Breast06 (DB-06) post-hoc analysis by physician's choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC)
6个月前
已关闭
Cost-effective use of BISphosphonates in metastatic bone disease - a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule
6个月前
已关闭
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
6个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
10个月前
已完结
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
10个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
10个月前
已完结
皖公网安备34019202002308
